CERE — Cerevel Therapeutics Holdings Income Statement
0.000.00%
Last trade - 00:00- $8.19bn
- $7.68bn
- 36
- 15
- 91
- 44
Annual income statement for Cerevel Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | — | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | — | 149 | 220 | 368 | 447 |
| Operating Profit | 0 | -149 | -220 | -368 | -447 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | — | -152 | -225 | -351 | -432 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | — | -152 | -225 | -352 | -433 |
| Net Income Before Extraordinary Items | |||||
| Net Income | — | -152 | -225 | -352 | -433 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | 0 | -148 | -225 | -352 | -433 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | — | -2.01 | -1.65 | -2.32 | -2.67 |